CSX Corp. $350 Million Senior Unsecured Notes Rated 'BBB' May 11

  • ID: 1807844
  • May 2011
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) May 27, 2011--Standard & Poor's Ratings Services said today that it has assigned its 'BBB' issue-level rating to CSX Corp.'s $350 million senior unsecured notes due 2021. CSX will use proceeds from the debt issuance for repayment of outstanding indebtedness, repurchases of common stock, capital expenditures, working capital requirements, and general corporate purposes. The ratings on Jacksonville, Fla.-based CSX reflect the company's strong competitive position as one of the two large eastern U.S. freight railroads. The favorable characteristics of the North American freight railroad industry include limited cyclicality, high barriers to entry, and access to low-cost equipment financing. Price competition from other railroads and trucking companies, as well as the capital intensity of the industry,...

Companies mentioned in this report are: CSX Corp.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

CSX Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.